Contents

Issue 123 • October 2022

In association with

In association with

Exploring the promise of billion-dollar KRAS drugs

KRAS mutations are one of the most prevalent drivers of cancer, yet they were long considered ‘undruggable’. A new wave of drugs is changing that.

IN DEPTH

Nanorobots: small solutions to big delivery problems

Comment

Brazil: an untapped market for big pharma manufacturing

Briefing

Industry news

Pharma industry briefing

Comment

The potential of virtual reality-based therapy for serious mental disorders

Brazil: an untapped market for big pharma manufacturing

More big wins for the AstraZeneca-Daiichi Sankyo collaboration

Dry powder inhalers carry potential to decrease greenhouse gas emissions

Black participants severely underrepresented in global oncology studies

Polio outbreak in New York state due to low vaccination coverage

In Depth

Exploring the promise of billion-dollar KRAS drugs

Nanorobots: small solutions to big delivery problems

Foreign investments amplify the nucleic acid therapeutics field

Going beyond the mirage of complete skin clearance in psoriasis

As Russia’s clinical trials sector falls, Ukraine rebuilds

CMO Moves: Regulatory catalysts for drug manufacturing- September

In Data

Top pharma companies best positioned to weather industry disruption

Which pharma companies lead the way in artificial intelligence?

North America sees a hiring jump in big data roles in pharma

Cloud computing mentions decrease in pharma filings

02/24/2024 12:20:46
  • Home | The promise of billion-dollar KRAS drugs
  • In this issue
  • Contents
  • Wek-tec Company Insight
  • CSafe Global
  • Briefing
  • Industry news
  • The pharma industry briefing
  • SHL Medical Company Insight
  • SHL Medical
  • Agilent
  • Comment
  • The potential of virtual reality-based therapy for serious mental disorders
  • Brazil: an untapped market for big pharma manufacturing
  • More big wins for the AstraZeneca-Daiichi Sankyo collaboration
  • Dry powder inhalers carry potential to decrease greenhouse emissions
  • Black participants severely underrepresented in global oncology studies
  • Polio outbreak in New York state due to low vaccination coverage
  • Mimotopes Company Insight
  • Mimotopes
  • Skyepharma
  • In Depth
  • Exploring the promise of billion-dollar KRAS drugs
  • Nanorobots: small solutions to big delivery problems
  • Foreign investments amplify the nucleic acid therapeutics field
  • Going beyond the mirage of complete skin clearance in psoriasis
  • As Russia’s clinical trials sector falls, Ukraine rebuilds
  • CMO Moves: Regulatory catalysts for drug manufacturing—September
  • Dr. Paul Lohmann
  • Baxter
  • In Data
  • Top pharma companies best positioned to weather industry disruption
  • Which pharma companies lead the way in artificial intelligence?
  • North America sees a hiring jump in big data roles in pharma
  • Cloud computing mentions decrease in pharma filings
  • Events
  • Next issue
09/21/2022 00:00:00